Get the Stockscreener App
2.12
0.00%
0.00
After Hours:
2.12
Werewolf Therapeutics Inc stock is traded at $2.12, with a volume of 99,980.
It is up +0.00% in the last 24 hours and down -1.85% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$2.12
Open:
$2.12
24h Volume:
99,980
Relative Volume:
0.38
Market Cap:
$91.77M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-1.6693
EPS:
-1.27
Net Cash Flow:
$-33.38M
1W Performance:
+0.95%
1M Performance:
-1.85%
6M Performance:
-67.28%
1Y Performance:
-0.93%
1-Day Range:
$2.06
$2.17
1-Week Range:
$1.90
$2.24
52-Week Range:
$1.5735
$8.1939
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Rubric Capital Management LP Has $3.26 Million Stock Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Trading Down 3.6% - MarketBeat
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Are Smart Investors Making the Right Decision? Werewolf Therapeutics Inc (HOWL) - SETE News
Market Recap Check: Werewolf Therapeutics Inc (HOWL)’s Negative Finish at 2.16, Up/Down -2.70 - The Dwinnex
What is the investor’s view on Werewolf Therapeutics Inc (HOWL)? - US Post News
Analysts Offer Predictions for Werewolf Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:HOWL) - MarketBeat
Analysts Issue Forecasts for Werewolf Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:HOWL) - MarketBeat
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Forecasted to Post Q3 2024 Earnings of ($0.45) Per Share - MarketBeat
Brokers Issue Forecasts for Werewolf Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:HOWL) - Defense World
Vanguard Group Inc. Boosts Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Yahoo Finance
1,688,054 Shares in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Bought by Janus Henderson Group PLC - MarketBeat
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly? - Simply Wall St
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Rises By 55.1% - Defense World
Hamilton Thorne Ltd. (OTCMKTS:HTLZF) Short Interest Update - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 55.1% in July - MarketBeat
Acadian Asset Management LLC Boosts Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics Inc (HOWL) Stock: A Year of Market Fluctuations - The InvestChronicle
WEREWOLF THERAPEUTICS, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
RSI Oversold: 2 Stocks (HOWL, WKHS) Potentially Signaling a Contrarian Buy - Nasdaq
CFRA maintains sell on Rivian, price target at $8 By Investing.com - Investing.com India
H.C. Wainwright: Werewolf Therapeutics stock weakness 'misplaced'; reiterates buy - Investing.com
Werewolf Therapeutics (NASDAQ:HOWL) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright: Werewolf Therapeutics stock weakness 'misplaced'; reiterates buy By Investing.com - Investing.com UK
Werewolf Therapeutics (NASDAQ:HOWL) Rating Reiterated by HC Wainwright - Defense World
Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1 (HOWL) - Seeking Alpha
Financial Fitness Check: Examining Werewolf Therapeutics Inc (HOWL)'s Key Ratios – DWinneX - The Dwinnex
Werewolf Therapeutics Inc (HOWL) can make a big difference with a little luck – Sete News - SETE News
A stock that deserves closer examination: Werewolf Therapeutics Inc (HOWL) – US Post News - US Post News
Werewolf Therapeutics (NASDAQ:HOWL) Receives Buy Rating from HC Wainwright - Defense World
Werewolf Therapeutics (NASDAQ:HOWL) Receives “Market Outperform” Rating from JMP Securities - Defense World
Werewolf Therapeutics shares hold Buy rating By Investing.com - Investing.com Australia
Werewolf Therapeutics' (HOWL) Market Outperform Rating Reiterated at JMP Securities - MarketBeat
Flutter Entertainment announces total voting rights By Investing.com - Investing.com
Citi starts United Rentals shares coverage with buy rating, cites solid outlook By Investing.com - Investing.com South Africa
Werewolf Therapeutics shares hold Buy rating By Investing.com - Investing.com UK
Where Werewolf Therapeutics Stands With Analysts - Benzinga
Werewolf Therapeutics stock target held by BofA on early data - Investing.com
Werewolf Therapeutics Inc's Market Journey: Closing Weak at 2.34, Down -10.34 – DWinneX - The Dwinnex
Werewolf Therapeutics Reports Promising WTX-330 Trial Outcomes - TipRanks
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating ... - GlobeNewswire
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - ForexTV.com
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - Yahoo Finance
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - GlobeNewswire
Closing Bell Recap: Werewolf Therapeutics Inc (HOWL) Ends at 2.89, Reflecting a -7.67 Downturn – DWinneX - The Dwinnex
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 26.1% in May - MarketBeat
SmartKem Executives Receive Stock Options and Cash Bonuses By Investing.com - Investing.com
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):